Ellen Sher, MD
Allergy & Immunology · Ocean, NJNPI 1710961602
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $672,122 of the $1,019,856 with a category attached, or 65.9%. 41 manufacturers reported payments, led by AstraZeneca at 29.8% of the total. 2025 is the largest year on record at $223,652, 3.2 times the $70,478 reported in 2019. Among allergy & immunology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,367 payments — averaging $746.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$304K
- GSK$200K
- Regeneron Healthcare Solutions, Inc.$97K
- Sanofi$88K
- Genentech USA, Inc.$54K
- ARS Pharmaceuticals Operations, Inc.$53K
- plus $224K from 35 others
Across 314 payments — averaging $5512.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$583K
- Aimmune Therapeutics, Inc.$471K
- Regeneron$261K
- Astrazeneca UK Limited$98K
- Merck$91K
- Shire North American Group Inc$46K
- plus $181K from 10 others
What the payments were for
- Consulting fees$200,09220%
- Speaking & faculty fees$672,12266%
- Travel & lodging$116,90711%
- Food & beverage$30,4763%
- Education$2590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$179,719
- TEZSPIRE$119,743
- NUCALA$99,316
- AIRSUPRA$77,462
- FASENRA$71,268
- TRELEGY ELLIPTA$65,895
- XOLAIR$55,547
- NEFFY$53,131
- Rinvoq$47,476
- OPZELURA$32,458
- Xhance$26,175
- PALFORZIA$21,993
- EBGLYSS$15,235
- AirDuo RespiClick$4,540
- ProAir Digihaler$4,540
- ArmonAir Digihaler$4,540
- CINQAIR$4,219
- RUCONEST$4,154
- Orladeyo$3,025
- Rhapsido$2,555
How this compares
$1,019,856 in reported general payments places this provider in the 95th percentile of 135 allergy & immunology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 15 | $717,388 |
| Dupixent SyringeDupilumab | 57 | $226,179 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 71 | $69,153 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $19,070 |
| Advair HfaFluticasone Propion/Salmeterol | 26 | $18,858 |
| Spiriva RespimatTiotropium Bromide | 14 | $15,299 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 43 | $11,542 |
| DuleraMometasone/Formoterol | 19 | $10,582 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $10,574 |
| Epinephrine | 39 | $9,175 |
| Arnuity ElliptaFluticasone Furoate | 13 | $8,028 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,719 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $6,674 |
| Azelastine Hcl | 108 | $5,228 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $4,935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $464 | $717,38815 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $199,570 | $96,251127 claims |
| Boehringer IngelheimSpiriva Respimat | $3,642 | $15,29914 claims |
| MerckDulera | $17 | $10,58219 claims |
| AstraZenecaSymbicort | $303,977 | $6,71917 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $8,993 | $6,67413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Ocean
- Jacqueline RossOcean$131K
- Gary GrossOcean$10K
- Peter RickettiTrenton$457K
- John KimMedford$339K
- Tina ZeccaLittle Silver$262K
- George BelecanechVoorhees$208K
- Shirin JadidiMendham$98K
- Mark WeinsteinBelleville$88K
- Joseph GrizzantiHawthorne$79K
- Lisa BariscianoFlorham Park$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.